Bruker Co. (NASDAQ:BRKR) Shares Bought by Point72 DIFC Ltd

Point72 DIFC Ltd increased its stake in shares of Bruker Co. (NASDAQ:BRKR) by 4,875.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,171 shares of the medical research company’s stock after buying an additional 460,722 shares during the quarter. Bruker comprises approximately 1.1% of Point72 DIFC Ltd’s investment portfolio, making the stock its biggest position. Point72 DIFC Ltd owned about 0.31% of Bruker worth $32,470,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its position in Bruker by 20.0% during the second quarter. Nisa Investment Advisors LLC now owns 991 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 165 shares in the last quarter. Securian Asset Management Inc. lifted its position in shares of Bruker by 2.3% during the 2nd quarter. Securian Asset Management Inc. now owns 7,766 shares of the medical research company’s stock worth $496,000 after buying an additional 175 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in Bruker by 120.4% in the second quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock valued at $25,000 after buying an additional 218 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in Bruker by 0.8% in the second quarter. Ameritas Investment Partners Inc. now owns 30,911 shares of the medical research company’s stock valued at $1,972,000 after acquiring an additional 235 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Bruker by 40.7% in the first quarter. EverSource Wealth Advisors LLC now owns 858 shares of the medical research company’s stock worth $81,000 after acquiring an additional 248 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Down 1.4 %

BRKR opened at $57.55 on Wednesday. Bruker Co. has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a fifty day moving average of $60.23 and a 200-day moving average of $63.67. The stock has a market cap of $8.72 billion, a PE ratio of 27.67, a price-to-earnings-growth ratio of 3.92 and a beta of 1.18. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. During the same quarter in the previous year, the business posted $0.74 earnings per share. The business’s revenue was up 16.4% on a year-over-year basis. On average, sell-side analysts predict that Bruker Co. will post 2.4 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Monday, December 2nd. Bruker’s payout ratio is 9.62%.

Insider Transactions at Bruker

In other news, CEO Frank H. Laukien bought 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The stock was bought at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the purchase, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This represents a 0.26 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 28.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Wolfe Research cut shares of Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. TD Cowen dropped their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Barclays cut their price objective on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Wells Fargo & Company lowered their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Finally, Citigroup reduced their price target on Bruker from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $79.36.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.